title: Inflammatory bowel disease surgery in the biologic era.
abstract: Anti-tumour necrosis factor (TNF)-α therapy has revolutionized inflammatory bowel disease (IBD) treatment. Infliximab and adalimumab either as monotherapy or in combination with an immunomodulator are able to induce clinical and biological remission in patients with moderate and severe Crohn's disease (CD) and ulcerative colitis (UC). These new therapies have led to a shift in the goals of IBD management from just controlling clinical symptoms to preventing disease progression. However, despite these advances in medical therapy, surgery is still required in 30%-40% of patients with CD and 20%-30% of patients with UC at some point during their lifetime. While biologics certainly play a major role in the medical treatment of IBD, there is concern about the effects of these anti-TNF-α agents on postoperative complications and morbidity. The purpose of this article is to review the role of surgery in the treatment of IBD in the age of biologics and the impact of these medications on per-operative outcomes. In this manuscript we review the relationship between biologic agents and surgery in the treatment of IBD. We also discuss in detail the periopetative risks and complications.
authors.affiliation: Linda Ferrari, Mukta K Krane, Alessandro Fichera, University of Washington Medical Center, Seattle, WA 98195-6410, United States.
authors.forename: Linda
authors.initials: L
authors.lastname: Ferrari
authors.affiliation: Linda Ferrari, Mukta K Krane, Alessandro Fichera, University of Washington Medical Center, Seattle, WA 98195-6410, United States.
authors.forename: Mukta K
authors.initials: MK
authors.lastname: Krane
authors.affiliation: Linda Ferrari, Mukta K Krane, Alessandro Fichera, University of Washington Medical Center, Seattle, WA 98195-6410, United States.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Fichera
keywords: Anti-tumour necrosis factor alpha agents; Crohn’s disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis